Adaptive and maladaptive roles of different angiotensin receptors in the development of cardiac hypertrophy and heart failure

被引:4
|
作者
Bhullar, Sukhwinder K.
Dhalla, Naranjan S. [1 ]
机构
[1] Univ Manitoba, St Boniface Hosp, Inst Cardiovasc Sci, Albrechtsen Res Ctr, Winnipeg, MB, Canada
关键词
angiotensin II; angiotensin II receptors; adaptive cardiac hypertrophy; maladaptive cardiac hypertrophy; heart failure; II TYPE-2 RECEPTOR; LEFT-VENTRICULAR HYPERTROPHY; ROSTRAL VENTROLATERAL MEDULLA; CONVERTING ENZYME-INHIBITORS; SYMPATHETIC AFFERENT REFLEX; VASCULAR SMOOTH-MUSCLE; OXIDATIVE STRESS; BLOOD-PRESSURE; AT(1) RECEPTOR; AT(2) RECEPTORS;
D O I
10.1139/cjpp-2023-0226
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Angiotensin II (Ang II) is formed by the action of angiotensin-converting enzyme (ACE) in the renin-angiotensin system. This hormone is known to induce cardiac hypertrophy and heart failure and its actions are mediated by the interaction of both pro-and antihypertrophic Ang II receptors (AT1R and AT2R). Ang II is also metabolized by ACE 2 to Ang-(1-7), which elicits the activation of Mas receptors (MasR) for inducing antihypertrophic actions. Since heart failure under different pathophysiological situations is preceded by adaptive and maladaptive cardiac hypertrophy, we have reviewed the existing literature to gain some information regarding the roles of AT1R, AT2R, and MasR in both acute and chronic conditions of cardiac hypertrophy. It appears that the activation of AT1R may be involved in the development of adaptive and maladaptive cardiac hypertrophy as well as subsequent heart failure because both ACE inhibitors and AT1R antagonists exert beneficial effects. On the other hand, the activation of both AT2R and MasR may prevent the occurrence of maladaptive cardiac hypertrophy and delay the progression of heart failure, and thus therapy with different activators of these antihypertrophic receptors under chronic pathological stages may prove beneficial. Accordingly, it is suggested that a great deal of effort should be made to develop appropriate activators of both AT2R and MasR for the treatment of heart failure subjects.
引用
收藏
页码:86 / 104
页数:19
相关论文
共 50 条
  • [31] The Cardiac Microvasculature in Hypertension, Cardiac Hypertrophy and Diastolic Heart Failure
    Hoenig, Michel R.
    Bianchi, Cesario
    Rosenzweig, Anthony
    Sellke, Frank W.
    CURRENT VASCULAR PHARMACOLOGY, 2008, 6 (04) : 292 - 300
  • [32] The nuclear receptor RORα protects against angiotensin II-induced cardiac hypertrophy and heart failure
    Beak, Ju Youn
    Kang, Hong Soon
    Huang, Wei
    Myers, Page H.
    Bowles, Dawn E.
    Jetten, Anton M.
    Jensen, Brian C.
    AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2019, 316 (01): : H186 - H200
  • [33] Cardiac-specific ablation of glutaredoxin 3 leads to cardiac hypertrophy and heart failure
    Donelson, Jimmonique
    Wang, Qiongling
    Monroe, Tanner O.
    Jiang, Xiqian
    Zhou, Jianjie
    Yu, Han
    Mo, Qianxing
    Sun, Qin
    Marini, Juan C.
    Wang, Xinquan
    Nakata, Paul A.
    Hirschi, Kendal D.
    Wang, Jin
    Rodney, George G.
    Wehrens, Xander Ht
    Cheng, Ninghui
    PHYSIOLOGICAL REPORTS, 2019, 7 (08):
  • [34] Relevance of angiotensin II for cardiac hypertrophy and failure induced by cardiac volume overload
    Ruzicka M.
    Leenen F.H.H.
    Heart Failure Reviews, 1999, 3 (3) : 169 - 181
  • [35] Oxidative Stress as A Mechanism for Functional Alterations in Cardiac Hypertrophy and Heart Failure
    Shah, Anureet K.
    Bhullar, Sukhwinder K.
    Elimban, Vijayan
    Dhalla, Naranjan S.
    ANTIOXIDANTS, 2021, 10 (06)
  • [36] Serotonin and Angiotensin Receptors in Cardiac Fibroblasts Coregulate Adrenergic-Dependent Cardiac Hypertrophy
    Jaffre, Fabrice
    Bonnin, Philippe
    Callebert, Jacques
    Debbabi, Haythem
    Setola, Vincent
    Doly, Stephane
    Monassier, Laurent
    Mettauer, Bertrand
    Blaxall, Burns C.
    Launay, Jean-Marie
    Maroteaux, Luc
    CIRCULATION RESEARCH, 2009, 104 (01) : 113 - U288
  • [37] Role of angiotensin AT1 and AT2 receptors in cardiac hypertrophy and cardiac remodelling
    Zhu, YC
    Zhu, YZ
    Lu, N
    Wang, MJ
    Wang, YX
    Yao, T
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2003, 30 (12) : 911 - 918
  • [38] Cardiac nuclear high mobility group box 1 prevents the development of cardiac hypertrophy and heart failure
    Funayama, Akira
    Shishido, Tetsuro
    Netsu, Shunsuke
    Narumi, Taro
    Kadowaki, Shinpei
    Takahashi, Hiroki
    Miyamoto, Takuya
    Watanabe, Tetsu
    Woo, Chang-Hoon
    Abe, Jun-ichi
    Kuwahara, Koichiro
    Nakao, Kazuwa
    Takeishi, Yasuchika
    Kubota, Isao
    CARDIOVASCULAR RESEARCH, 2013, 99 (04) : 657 - 664
  • [39] Distinct functions of junD in cardiac hypertrophy and heart failure
    Ricci, R
    Eriksson, U
    Oudit, GY
    Eferl, R
    Akhmedov, A
    Sumara, I
    Sumara, G
    Kassiri, Z
    David, JP
    Bakiri, L
    Sasse, B
    Idarraga, MH
    Rath, M
    Kurz, D
    Theussl, HC
    Perriard, JC
    Backx, P
    Penninger, JM
    Wagner, EF
    GENES & DEVELOPMENT, 2005, 19 (02) : 208 - 213
  • [40] Alterations in calcium handling in cardiac hypertrophy and heart failure
    Balke, CW
    Shorofsky, SR
    CARDIOVASCULAR RESEARCH, 1998, 37 (02) : 290 - 299